Answers are grounded in this paper and cite their sources.
Angiogenic imbalance-induced endothelial dysfunction is central to pre-eclampsia (PE) pathogenesis. A disintegrin and metalloprotease with thrombospondin motif, member 7 (ADAMTS7) is upregulated in PE placentas and suppresses trophoblast function; however, its role in systemic endothelial dysfunction during PE remains unclear. Here we show a higher placental secretion and plasma level of ADAMTS7 in PE patients. ADAMTS7 circulating levels are positively correlated with systolic and diastolic blood pressure of pregnant women. Besides, hypoxia stimulates ADAMTS7 expression in human trophoblast and vascular cells by a HIF1α-dependent way. Pregnant rats with ADAMTS7 overexpression by adenovirus injection exhibits PE-like symptoms and impaired placental development. Functionally, ADAMTS7 significantly inhibits endothelial angiogenic activity and suppresses vessel formation as evidenced by proliferation, migration, angiogenic assays. Mechanistically, ADAMTS7 binds to and decreases periostin (POSTN), reducing VEGFR2 expression and phosphorylation. This study identifies ADAMTS7 as a pathogenic factor in PE that impaired endothelial angiogenic function, suggesting that targeting ADAMTS7/POSTN/VEGFR2 axis may represent a promising therapeutic strategy for PE. Angiogenic imbalance drives endothelial dysfunction in pre-eclampsia (PE). Here, the authors show the metalloprotease ADAMTS7 is elevated in the circulation of PE patients and impairs endothelial angiogenic function, suggesting the ADAMTS7/POSTN/VEGFR2 axis as a therapeutic target for PE.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: